Major Depressive Disorder Clinical Trial
— TRIAGE-PsychOfficial title:
Triage Survey for Psychiatry Research Eligibility
TRIAGE-Psych is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored psychiatry clinical trials.
Status | Recruiting |
Enrollment | 2000 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participant or Legally Authorized Representative has signed an ICF prior to study-specific procedures being performed. - Participant is at least 18 years old. Exclusion Criteria: - Participant is pregnant, breast-feeding, or planning to become pregnant. - History of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results. - Participant represents an acute suicidal risk, as defined as a "yes" response to ideation on C-SSRS questions 4 or 5, or answer "yes" to behavior questions within 90 days of screening. - Moderate or severe substance use disorder within 90 days prior to screen, according to DSM-5 criteria that in the investigator's opinion could pose undue risk to the participant. - Any condition that in the investigator's opinion makes a participant unsuitable for the study. - Currently employed by Adams Clinical or a first-degree relative of an employee. |
Country | Name | City | State |
---|---|---|---|
United States | Copley Clinical | Boston | Massachusetts |
United States | Berman Clinical | New York | New York |
United States | Adams Clinical | Watertown | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Adams Clinical |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The proportion of participants who are eligible for industry-sponsored clinical trials, as defined as those who go on to screen for a study | Up to 52 weeks | ||
Secondary | The proportion of participants who enroll in industry-sponsored clinical trials | Up to 52 weeks | ||
Secondary | The prevalence of disqualifying comorbid conditions that prevent screening or enrollment in industry-sponsored clinical trials | Up to 52 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |